Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Long-Term Investments
Gensight Biologics SA
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Long-Term Investments
€519k
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Long-Term Investments
€10.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
59%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Investments
€3.4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Long-Term Investments?
Long-Term Investments
519k
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Long-Term Investments amounts to 519k EUR.
What is Gensight Biologics SA's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
9%
Over the last year, the Long-Term Investments growth was -6%. The average annual Long-Term Investments growth rates for Gensight Biologics SA have been 17% over the past three years , 9% over the past five years .
You don't have any saved screeners yet